Ruixing layout of medical device hemophilia gene therapy of "medical fast reading society" is qualified for priority evaluation

[February 21, 2020 / medical information list] Junsai biology announced the completion of pre-A round of financing; GSK invested heavily in the layout of new tcr-t cell therapy; hispec ciprofol emulsion injection was proposed to be included in the priority review; thaling pharmaceutical "Shusi" passed the consistency evaluation Daily fresh medicine news, speed reading club and you pay attention to! As of 24:00 on February 20, according to the reports of 31 provinces (autonomous regions, municipalities directly under the central government) and Xinjiang production and Construction Corps, there are 54965 confirmed cases (including 11633 severe cases), 18264 cured and discharged cases, 2236 dead cases, 75465 confirmed cases and 5206 suspected cases There were 606037 close contacts and 120302 close contacts still under medical observation (official website of national health and Health Commission) Novel coronavirus pneumonia novel coronavirus pneumonia confirmed in Hubei prison system on 271 July, including 230 cases in Wuhan prison in Hubei province and 41 cases in Han Jin prison in Shayang, Hubei All cases were imported Recently, a new crown pneumonia outbreak occurred in Shandong city jail As of February 20th, the nucleic acid test of 2077 people in the prison has been completed, 207 cases were confirmed, among which, 21 cases were diagnosed There were 7 policemen and 200 prisoners (website of Hubei Provincial People's government, issued by Shandong) Zeng Yixin, deputy director of the National Health Commission, said Monday that the latest progress in vaccine research and development is the simultaneous development of five technical routes: inactivated vaccine, gene engineering recombinant subunit vaccine, adenovirus vector vaccine, nucleic acid vaccine and attenuated influenza virus vector vaccine Some vaccine projects have entered the stage of animal experiment (people's daily) On the 21st, baiaotai was listed on the Shanghai Stock Exchange's scientific innovation board The opening price was 60.00 yuan, 83.15% higher than the issue price of 32.76 yuan As of the date of issuance, the market value of the company is close to 24.928 billion According to the prospectus, no more than 60 million A-share common shares are planned to be publicly issued at a price of 32.76 yuan / share, mainly for drug research and development (Insight database) Recently, the listing application draft of science and technology innovation board submitted by kangxinuo shows that it has entered the "inquired" state As early as 2014, as a result of the successful development of the "first Asian" Ebola vaccine, the 5-year-old conchino has become famous and stands on the stage of the world's top innovative vaccine research and development (shell Society) Recently, imatics, a biopharmaceutical company, is working with GSK to develop new adoptive cell therapy for various tumor indications Under the terms of the deal, GSK will pay imatics about $50 million in advance of two initial plans (Sina Medical News) Recently, the business scope of Ruixing coffee (Beijing) Co., Ltd has changed, with the words "retail drugs" and "sales of medical devices of class I and class II" and other medical related words appearing "In the near future, people's daily purchase of medicine and equipment may also be related to Ruixing," said Qian Zhiya, CEO of Ruixing coffee (billion euro) Recently, Shanghai Junsai Biotechnology Co., Ltd has successfully completed tens of millions of RMB pre-A rounds of financing This round of financing is led by Yuanhe origin, followed by re capacity investment and investment Haoyue capital is the exclusive financial consultant of this round of financing Dr Jin Huajun, the founder of the company, said that the round of financing funds will be used for research and development of a number of new til cell therapies (arterial network) Recently, spruce Biosciences, a company dedicated to the treatment of rare endocrine diseases, announced the completion of round B financing of US $88 million to promote the development of its oral corticotropin releasing factor receptor antagonist tildacerfont in the treatment of congenital adrenal hyperplasia and other indications (chuangjianhui) On the 20th, Hengrui registered and launched the stage IB clinical study of safety and tolerance of shr-1701 in the treatment of recurrent or metastatic NPC patients, and planned to enroll 40 patients It is reported that this study is an open, non randomized, single arm domestic trial, with the primary end point being safety of shr-1701 (medicine cube) accurate 21, the novel coronavirus pneumonia clinical trial of BDB-001 and its wholly owned subsidiary, de Fung Rui, was released on the day of the announcement The Ib phase clinical trial of the new injection of BDB-001 injection to the new crown pneumonia has been approved by the ethics committee of the third people's Hospital of Hainan (notice of Shu Taishen) Hebei Renhe Yikang Pharmaceutical Co., Ltd has recently issued an application for listing four types of salbutamol sulfate solution for inhalation, which is expected to be approved and deemed as having been evaluated It is reported that the original research enterprise of the product is GSK, and Hebei Renhe Yikang Pharmaceutical Co., Ltd will further seize the original research market after it is approved as the first evaluated enterprise according to the new classification (meter net) Recently, according to nmpa official website, the listing application of three generic drugs of alfentanil hydrochloride injection declared by humanwell pharmaceutical has been in the state of "approval", and is expected to be approved for listing in the near future It is reported that alfentanil hydrochloride injection is a powerful analgesic used in anesthesia and is suitable for short-term operations (CPHI Pharma online) "Shusi", a compound drug used to treat bipolar disorder by Suzhou No.1 Pharmaceutical Co., Ltd., a subsidiary of the company, recently passed the consistency evaluation approved by the State Food and drug administration, according to a notice issued by tailing pharmaceutical on Tuesday (notice of tailing pharmaceutical) On February 20, hisic announced that the ciprofol emulsion injection of Sichuan hisic Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, was included in the list of "publicity of proposed priority review varieties" by the drug review center of the State Drug Administration, and the publicity deadline is February 27, 2020 (HISCO announcement) Biomarin pharmaceutical announced Monday that the US FDA has accepted its application for permission to use biologicals for valoc tococogene roxaparvovec, a gene therapy for hemophilia A a The FDA has granted this application priority review qualification, and is expected to respond before August 21 this year (yaomingkant) Recently, karyopharm therapeutics announced that the U.S FDA has accepted the company's application for additional new drugs for xpovio This application seeks to accelerate the approval of xpovio for the treatment of relapsed / refractory diffuse large B-cell lymphoma The FDA has granted this application priority review qualification and is expected to respond by June 23 this year (yaomingkant) On Tuesday, the CDE official website showed that three innovative drugs with obvious therapeutic advantages declared by Bayer in China were to be included in the priority review according to the priority review scope (1) It is reported that the drug has been approved by FDA on July 30, 2019, for the treatment of non metastatic castration resistant prostate cancer patients (medicine cube)